{"id":"W3157950444","doi":"10.1200/jco.20.02822","title":"Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Seagen (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Pertuzumab; Metastatic breast cancer; Internal medicine; Clinical endpoint; Oncology; Brain metastasis; Adverse effect; Breast cancer; Cancer; Phases of clinical research; Radiation therapy; Chemotherapy; Surgery; Metastasis; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002728574,0.0009408036,0.001518491,0.0003404527,0.0002572928,0.00101747,0.000525783,0.000648394,0.00154992],"category_scores_gemma":[0.001454444,0.0003298755,0.001626512,0.0004600324,0.0005693736,0.0005332825,0.0003533882,0.001697325,0.000420872],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009945413,"about_ca_system_score_gemma":0.001978836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008027205,"about_ca_topic_score_gemma":0.001719744,"domain_scores_codex":[0.9992143,0.0004263133,0.0000467027,0.0001067216,0.0001095542,0.00009632781],"domain_scores_gemma":[0.9990141,0.0001546877,0.0002467803,0.00007237775,0.0000969083,0.0004151335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7061024,0.05808206,0.05255591,0.002079349,0.007908107,0.000828809,0.0005303323,0.002355103,0.02218648,0.0003182793,0.004156325,0.1428967],"study_design_scores_gemma":[0.5394824,0.3744304,0.07488487,0.0001200578,0.002259754,0.0007613934,0.00008216307,0.001406524,0.002161146,0.0001834606,0.004189403,0.00003857154],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992547,0.003800719,0.0003633356,0.000254916,0.00004835847,0.001579488,0.0005349537,0.00002908081,0.0008420764],"genre_scores_gemma":[0.9916173,0.002658233,0.000727455,0.000667114,0.000161779,0.001624291,0.001711219,0.00001186165,0.0008206777],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002728574,"threshold_uncertainty_score":0.01443028,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04527426126557866,"score_gpt":0.4341522077045012,"score_spread":0.3888779464389226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}